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Case repOrt
Only rare cases of anti-Vel–associated mild-to-moderate 
hemolytic disease of the fetus and newborn have been previously 
reported. No case of fetal anemia requiring prenatal therapy has 
been noted to date. We report such a case recently encountered 
at our Fetal Center. Strategies are discussed for managing 
pregnancy complicated with alloimmunization to an antibody 
to a high-prevalence antigen, including sources of red blood 
cells for intrauterine transfusions. Immunohematology 
2017;33:152–154.
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The Vel red blood cell (RBC) antigen was first described in 
1952.1 The antigen is ubiquitous in the general population, with 
only 0.04 percent of Caucasian individuals failing to exhibit 
expression.2 Only rare cases of anti-Vel–associated mild-to-
moderate hemolytic disease of the fetus and newborn (HDFN) 
have been previously reported.3–7 The neonatal manifestation 
of HDFN in these cases was limited to hyperbilirubinemia 
requiring only phototherapy. No case of fetal anemia requiring 
prenatal therapy has been noted to date. We report such a case 
recently encountered at our Fetal Center. 
Case Report
The patient was a 31-year-old woman (gravida/
para/abortus [GPA] = G2P1000) who was referred to our 
Fetal Center from a neighboring state for evaluation of Vel 
alloimmunization. Her past history was significant, with the 
finding of a positive antibody detection test and identification 
of anti-Vel during her previous pregnancy. Based on literature 
reports of only mild-to-moderate HDFN in association with 
Vel alloimmunization, the patient’s obstetrician had elected 
to follow the previous pregnancy conservatively. The patient 
was delivered by vaginal birth at 39 6/7 weeks of gestation. 
The neonate was noted to exhibit severe anemia and was 
transferred to a tertiary level nursery. After a stormy neonatal 
course that was complicated by pulmonary hypertension, the 
neonate died on day 13 of life.
In the patient’s current pregnancy, her anti-Vel titer was 
32 at 11 weeks of gestation. A repeat at our regional blood 
center indicated a titer of 4. Consideration was given to begin 
a plasmapheresis/intravenous immune globulin treatment; 
given the patient’s low titer, however, this was not felt to be 
indicated. The patient returned to her local maternal-fetal 
medicine specialist and was followed with weekly middle 
cerebral artery Doppler ultrasounds to measure the peak 
systolic velocity (MCA-PSV). She was encouraged to donate 
autologous RBC units in anticipation of a possible need for 
intrauterine transfusion later in gestation. The patient was able 
to donate 4 units; these were kept refrigerated for 3–5 days and 
then frozen at the local blood center. At 24 weeks of gestation, 
the MCA-PSV became elevated to 1.89 multiples of the median 
(MoM), and the patient was referred back to our Fetal Center 
(>1.5 MoM is indicative of severe fetal anemia8). A repeat 
MCA-PSV was 2.0 MoM, and the repeat maternal anti-Vel 
titer was 16. A decision was made to proceed with intrauterine 
transfusion. Arrangements were made for transport of the 
previously donated frozen maternal RBC units to our regional 
blood center. Initial sampling at the time of cordocentesis at 24 
1/7 weeks of gestation revealed a fetal hematocrit (Hct) of 11.8 
percent (normal 36%) with a reticulocyte count of 14.7 percent 
(normal <2%). RBC typing indicated the fetus to be Vel+. 
One unit of maternal autologous RBCs was deglycerolized, 
irradiated, washed, and reconstituted with normal saline 
to achieve an Hct of 72 percent in the final blood product. A 
60-mL intravascular transfusion combined with a 40-mL 
intraperitoneal transfusion was performed successfully. A total 
of five intrauterine transfusions were subsequently undertaken 
(Fig. 1). The patient donated 3 additional RBC units during 
the remainder of the pregnancy and maintained an Hct above 
32 percent, with oral iron and folate supplementation. The 
additional RBC units for intrauterine transfusion came from 
a single local blood donor (2 frozen, 1 fresh) and another rare 
registry donor (1 fresh). The patient was delivered uneventfully 
by repeat caesarean section at 37 6/7 weeks of gestation of a 
4235-gram male infant with Apgar scores of 8 and 9. The infant 
was noted to have an Hct of 46.2 percent (normal 53%) with a 
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reticulocyte count of 2 percent (normal <7%) and a Kleihauer-
Betke stain indicating 3.7 percent fetal cells remaining in the 
infant’s circulation (normal 100%). The neonatal course was 
benign and required only treatment with bili light therapy for 
3 days; the maximum total bilirubin was 10.6 mg/dL (normal 
6.5 mg/dL). He was discharged on day 7 of life. The infant was 
followed weekly by a local pediatric hematologist. He required 
one top-up transfusion at 5 weeks of age and was released by 
the pediatric hematologist at 9 weeks of age.
Discussion
Our case illustrates at least three important points. Vel 
is expressed on fetal RBCs as early as 12 weeks of life; its 
strength appears to be equivalent to that on adult RBCs.9 
Because alloimmunization to this antigen is so rare and only 
a few case reports of HDFN have been reported to date, it is 
difficult to determine a “critical titer” for this entity. Often, 
anti-Vel is only IgM, which would not present a risk for 
HDFN because transplacental passage cannot occur. Linz 
et al.10 recommended treatment with 2-mercaptoethanol 
or dithiothreitol to determine whether an IgG component is 
present. Both IgG and IgM had been detected in our case. A 
predominance of IgG in our case may well explain the severe 
degree of HDFN. One should assume that a paternal Vel 
antigen will be inherited by the fetus, given that Vel is a high-
prevalence antigen. Thus, it would appear prudent to institute 
serial MCA-PSV determinations in the early second trimester 
in the rare case that anti-Vel is detected during pregnancy.
The strategy in obtaining sufficient RBC units for 
intrauterine transfusion to treat the HDFN is also an 
essential element of our case. The high prevalence of Vel 
makes finding Vel– donors extremely difficult. The patient 
was evaluated before pregnancy, and no sibling or family 
member was identified as a potential donor. A search by our 
regional blood center found only one eligible donor locally. 
The patient was instructed to undergo autologous donations 
in the early part of pregnancy and was able to donate 4 units. 
Iron and folate supplementation was initiated in advance. We 
previously reported a series of 21 patients who donated 77 
units of autologous blood as a source of RBCs for intrauterine 
transfusion in the pre-HIV testing era.11 Three of the patients 
in that series were able to donate 6 units with maintenance 
of their baseline Hct levels. In our case, we were able to have 
our patient donate 7 units while maintaining her Hct with 
hematopoietic pharmacologic supplementation. Because 
freshly donated RBCs are typically preferred as a source for 
intrauterine transfusion, we defined the specific time for the 
final 3 units of autologous donation and arranged allogeneic 
donation times so that fresh blood was used for the scheduled 
intrauterine transfusions. Our experience in timed blood 
preparation would be useful in managing similar patients.
Finally, at delivery, we had multidisciplinary commu-
nication. To prepare for the urgent need for blood as well as to 
prevent wasting the rare blood product, we secured 2 frozen 
autologous compatible RBC units in our regional blood center 
before the scheduled caesarean delivery. In the event of an 
acute postpartum hemorrhage, we developed a plan with 
our blood bank for the emergency release of ABO-compatible 
RBCs pending the deglycerolization of these frozen units.
Fig. 1 Timeline of diagnostic testing and subsequent treatments. w = weeks; d = days; MoM = multiples of the median; IUT = intrauterine 
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